Ifeanyichukwu Ifechidere: DOAC Monitoring – What To Order, When, And Why
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“Not every patient on a DOAC needs monitoring.
But when they do, ordering the wrong assay can lead to the wrong clinical decision.
This is where many clinicians-and even laboratories-get caught out.
The question isn’t just ‘Should I measure the DOAC?’
It’s ‘Which assay answers my clinical question?’
Here’s a simple way to think about it:
- Anti-Xa assay
- Best for rivaroxaban, apixaban, and edoxaban
- Use a drug-specific calibrated Anti-Xa assay
- Helpful in major bleeding, urgent surgery, suspected overdose, renal impairment, or unexpected thrombosis.
Dilute Thrombin Time (dTT)
- Best for dabigatran
- Provides a quantitative estimate of dabigatran concentration.
- More reliable than routine clotting tests.
DOAC Screen
- Useful as a rapid screening tool to determine whether a clinically significant DOAC is present.
- Helpful in emergency settings when the anticoagulant history is uncertain.
- It is not a substitute for drug-specific quantification.
And here’s the part that’s often overlooked…
Timing matters just as much as assay selection.
A result is difficult to interpret unless you know:
- Which DOAC the patient is taking
- The dose
- The time of the last dose
- Renal function
- Whether you’re measuring a peak or trough level
Without that context, even the ‘right’ test can produce a misleading interpretation.
The takeaway:
The goal of DOAC testing isn’t simply to detect the drug.
It’s to answer a specific clinical question with the right assay at the right time.
What is the biggest challenge your laboratory or clinical team faces when interpreting DOAC assays?”

Find more posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Oct 2, 2026, 13:50Arnav Garcha: New Insights Into Platelet Transport in Arterial Flow
-
Oct 2, 2026, 13:49Alessandro Lucchesi: RiseMPN 2026 – Shaping the Future of MPN Treatment
-
Oct 2, 2026, 13:43Ronald Mahomane: Bangladesh Moves Toward Sustainable Hemophilia Treatment Access
-
Oct 2, 2026, 13:38Sathya-Prasad Burjonrappa: Pediatric Trauma and Deep Venous Thrombosis
-
Oct 2, 2026, 12:50Ravi C Dara: ADHAR 2026 – Red Cell Exchange in Sickle Cell Disease
-
Oct 2, 2026, 12:37David McIntosh: WeDonate Partners with Dr. Martens to Reward UK Blood Donors
-
Oct 2, 2026, 12:31Ahmed Salah El-Deen: HELLP Syndrome – An Obstetric Emergency
-
Oct 2, 2026, 12:28Swapnil Hiremath: Transitioning from Idiopathic Thrombocytopenia to Antiphospholipid Syndrome in Recurrent Severe Preeclampsia
-
Oct 2, 2026, 12:08Austin Camp: Learn How to Treat HIT from an ICU Pharmacist in 60 Seconds!